CD44 and hepatocellular carcinoma: Although the combination of sorafenib and GANT61 had little additive effect on CD44-negative HCC PDOs, a highly synergistic effect was observed after cotreatment of sorafenib and GANT61 in CD44-positive HCC PDOs (Fig. 5a).